Byramjee Jeejeebhoy Government Medical College - Johns Hopkins University Clinical Research Site, Jai Prakash Narayan Road, Maharashtra, 411001, Pune, India.
Department of Epidemiology, McGill University, Purvis Hall, 1020 Pine Avenue, Montreal, QC, H3G 1A2, Canada.
BMC Public Health. 2020 Oct 23;20(1):1598. doi: 10.1186/s12889-020-09656-8.
Globally, India has the third largest population of people living with HIV (PLHIV) and the second highest number of COVID-19 cases. Anxiety is associated with antiretroviral therapy (ART) nonadherence. It is crucial to understand the burden of anxiety and its sources among Asian Indian PLHIV during the COVID pandemic, but data are limited.
During the first month of government mandated lockdown, we administered an anxiety assessment via telephone among PLHIV registered for care at a publicly funded antiretroviral therapy (ART) center in Pune, India. Generalized anxiety was defined as GAD-7 score ≥ 10. Sociodemographic and clinical variables were compared by anxiety status (GAD-7 score ≥ 10 vs GAD-7 score < 10). Qualitative responses to an open-ended question about causes of concern were evaluated using thematic analysis.
Among 167 PLHIV, median age was 44 years (IQR 40-50); the majority were cisgender women (60%) and had a monthly family income < 200 USD (81%). Prior history of tuberculosis and other comorbidities were observed in 38 and 27%, respectively. Overall, prevalence of generalized anxiety was 25% (n = 41). PLHIV with GAD-7 score ≥ 10 had fewer remaining doses of ART than those with lower GAD-7 scores (p = 0.05). Thematic analysis indicated that concerns were both health related and unrelated, and stated temporally. Present concerns were often also projected as future concerns.
The burden of anxiety was high during COVID lockdown in our population of socioeconomically disadvantaged PLHIV in Pune and appeared to be influenced by concerns about ART availability. The burden of anxiety among PLHIV will likely increase with the worsening pandemic in India, as sources of anxiety are expected to persist. We recommend the regular use of short screening tools for anxiety to monitor and triage patients as an extension of current HIV services.
在全球范围内,印度拥有第三大艾滋病毒感染者(PLHIV)人群,也是 COVID-19 病例数第二高的国家。焦虑与抗逆转录病毒治疗(ART)不依从有关。了解在 COVID 大流行期间亚洲印度 PLHIV 的焦虑负担及其来源至关重要,但数据有限。
在政府强制封锁的第一个月,我们通过电话向在印度浦那一家公共资助的抗逆转录病毒治疗(ART)中心接受护理的 PLHIV 进行了焦虑评估。广泛性焦虑症定义为 GAD-7 评分≥10。根据焦虑状态(GAD-7 评分≥10 与 GAD-7 评分<10)比较社会人口统计学和临床变量。使用主题分析评估对有关担忧原因的开放式问题的定性回答。
在 167 名 PLHIV 中,中位年龄为 44 岁(IQR 40-50);大多数是跨性别女性(60%),家庭月收入<200 美元(81%)。分别有 38%和 27%的人有结核病和其他合并症病史。总体而言,广泛性焦虑症的患病率为 25%(n=41)。GAD-7 评分≥10 的 PLHIV 的 ART 剩余剂量少于 GAD-7 评分较低的 PLHIV(p=0.05)。主题分析表明,担忧既有与健康相关的,也有与健康无关的,而且是按时间顺序提出的。目前的担忧往往也被预测为未来的担忧。
在浦那社会经济弱势群体的 PLHIV 中,COVID 封锁期间焦虑负担很高,似乎受到对 ART 可用性的担忧的影响。随着印度大流行的恶化,PLHIV 的焦虑负担可能会增加,预计焦虑的来源将持续存在。我们建议定期使用简短的焦虑筛查工具来监测和分诊患者,作为当前 HIV 服务的扩展。